These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 35456462)

  • 1. Barth Syndrome Cardiomyopathy: An Update.
    Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
    Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
    Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Barth Syndrome Patient-Derived
    Snider PL; Sierra Potchanant EA; Sun Z; Edwards DM; Chan KK; Matias C; Awata J; Sheth A; Pride PM; Payne RM; Rubart M; Brault JJ; Chin MT; Nalepa G; Conway SJ
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
    Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
    J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
    Zhang J; Liu X; Nie J; Shi Y
    Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
    Sabbah HN
    Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
    Dinca AA; Chien WM; Chin MT
    J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome.
    Johnson JM; Ferrara PJ; Verkerke ARP; Coleman CB; Wentzler EJ; Neufer PD; Kew KA; de Castro Brás LE; Funai K
    J Mol Cell Cardiol; 2018 Aug; 121():94-102. PubMed ID: 30008435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barth syndrome.
    Jefferies JL
    Am J Med Genet C Semin Med Genet; 2013 Aug; 163C(3):198-205. PubMed ID: 23843353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental models of Barth syndrome.
    Pu WT
    J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
    Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
    Ji J; Greenberg ML
    J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
    Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
    J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
    Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
    J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barth syndrome mutations that cause tafazzin complex lability.
    Claypool SM; Whited K; Srijumnong S; Han X; Koehler CM
    J Cell Biol; 2011 Feb; 192(3):447-62. PubMed ID: 21300850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased mtDNA Abundance and Improved Function in Human Barth Syndrome Patient Fibroblasts Following AAV-
    Suzuki-Hatano S; Sriramvenugopal M; Ramanathan M; Soustek M; Byrne BJ; Cade WT; Kang PB; Pacak CA
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation.
    Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
    Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
    FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipid abnormalities in children with Barth syndrome.
    Schlame M; Kelley RI; Feigenbaum A; Towbin JA; Heerdt PM; Schieble T; Wanders RJ; DiMauro S; Blanck TJ
    J Am Coll Cardiol; 2003 Dec; 42(11):1994-9. PubMed ID: 14662265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between cardiolipin and plasmalogens in Barth syndrome.
    Bozelli JC; Epand RM
    J Inherit Metab Dis; 2022 Jan; 45(1):99-110. PubMed ID: 34655242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.